|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Imai H, Kaira K, Suzuki K, Anzai M, Tsuda
T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, et al: A
phase II study of afatinib treatment for elderly patients with
previously untreated advanced non-small-cell lung cancer harboring
EGFR mutations. Lung Cancer. 126:41–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brinkmeyer JK and Moore DC: Necitumumab
for the treatment of squamous cell non-small cell lung cancer. J
Oncol Pharm Pract. 24:37–41. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horn L, Reck M and Spigel DR: The Future
of immunotherapy in the treatment of small cell lung cancer.
Oncologist. 21:910–921. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dickson JL, Horst C, Nair A, Tisi S,
Prendecki R and Janes SM: Hesitancy around low-dose CT screening
for lung cancer. Ann Oncol. 33:34–41. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li M, Zhang Y, Jiang L, Li Y, Li G, Zhou
J, Yang C, Li X, Qu W, Chen Y, et al: New insights into the
diagnostic characteristics and clinical application of serum
biomarkers for lung cancer, and human epididymis protein 4 as a new
biomarker? Neoplasma. 69:729–740. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Z, Liu X, Shang X, Qi K and Zhang S:
The diagnostic value of the combination of carcinoembryonic
antigen, squamous cell carcinoma-related antigen, CYFRA 21-1,
neuron-specific enolase, tissue polypeptide antigen, and
progastrin-releasing peptide in small cell lung cancer
discrimination. Int J Biol Markers. 36:36–44. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kirchhoff C, Habben I, Ivell R and Krull
N: A major human epididymis-specific cDNA encodes a protein with
sequence homology to extracellular proteinase inhibitors. Biol
Reprod. 45:350–357. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bingle L, Singleton V and Bingle CD: The
putative ovarian tumour marker gene HE4 (WFDC2), is expressed in
normal tissues and undergoes complex alternative splicing to yield
multiple protein isoforms. Oncogene. 21:2768–2773. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drapkin R, von Horsten HH, Lin Y, Mok SC,
Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is
a secreted glycoprotein that is overexpressed by serous and
endometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Wang ZC, Luo L, Mu CY, Xu J, Feng Q,
Li SB, Gu B, Ma P and Lan T: The clinical value of the combined
detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer
diagnosis. Eur Rev Med Pharmacol Sci. 24:604–610. 2020.PubMed/NCBI
|
|
13
|
Wang H, Liu P, Xu H and Dai H: Early
diagonosis of ovarian cancer: Serum HE4, CA125 and ROMA model. Am J
Transl Res. 13:14141–14148. 2021.PubMed/NCBI
|
|
14
|
Plotti F, Guzzo F, Schirò T, Terranova C,
De Cicco Nardone C, Montera R, Luvero D, Scaletta G, Lopez S,
Capriglione S, et al: Role of human epididymis protein 4 (HE4) in
detecting recurrence in CA125 negative ovarian cancer patients. Int
J Gynecol Cancer. ijgc-2019-000211. 2019.(Epub ahead of print).
View Article : Google Scholar
|
|
15
|
Espiau Romera A, Coronado Martín PJ,
Chóliz Ezquerro M, Cuesta Guardiola T, Adiego Calvo I and Baquedano
Mainar L: Value of preoperative HE4 as predictor of advanced
disease in endometrioid endometrial cancer. Int J Gynaecol Obstet.
153:64–70. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng Q, Liu M, Zhou N, Liu L and Song X:
Serum human epididymis protein 4 (HE4) may be a better tumor marker
in early lung cancer. Clin Chim Acta. 455:102–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamy PJ, Plassot C and Pujol JL: Serum
HE4: An independent prognostic factor in non-small cell lung
cancer. PLoS One. 10:e01288362015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang B, Ren N, Guo B, Xin H and Yin Y:
Measuring serum human epididymis secretory protein autoantibody as
an early biomarker of lung cancer. Transl Cancer Res. 9:735–741.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iwahori K, Suzuki H, Kishi Y, Fujii Y,
Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I and Naka T:
Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Tumour Biol. 33:1141–1149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu W, Yang J, Chi PD, Zheng X, Dai SQ,
Chen H, Xu BL and Liu WL: Evaluating the clinical significance of
serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J
Tuberc Lung Dis. 17:1346–1353. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagy B Jr, Bhattoa HP, Steiber Z, Csobán
M, Szilasi M, Méhes G, Müller M, Lázár J, Kappelmayer J and
Antal-Szalmás P: Serum human epididymis protein 4 (HE4) as a tumor
marker in men with lung cancer. Clin Chem Lab Med. 52:1639–1648.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu L, Liu B, Zhu LL, Zhang W and Li Y:
Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity
in serum and pleural effusion of patients with squamous-cell lung
cancer. Bioanalysis. 4:2367–2374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du J, Li Y, Wang L, Zhou Y, Shen Y, Xu F
and Chen Y: Selective application of neuroendocrine markers in the
diagnosis and treatment of small cell lung cancer. Clin Chim Acta.
509:295–303. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ucar EY, Ozkaya AL, Araz O, Akgun M, Meral
M, Kaynar H, Saglam L, Aksoy H and Akcay F: Serum and bronchial
aspiration fluid HE-4 levels in lung cancer. Tumour Biol.
35:8795–8799. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hertlein L, Stieber P, Kirschenhofer A,
Krocker K, Nagel D, Lenhard M and Burges A: Human epididymis
protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab
Med. 50:2181–2188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gąsiorowska E, Magnowska M, Iżycka N,
Warchoł W and Nowak-Markwitz E: The role of HE4 in differentiating
benign and malignant endometrial pathology. Ginekol Pol.
87:260–264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang SW, Chen H, Dowdy S, Fu A, Attewell
J, Kalogera E, Drapkin R, Podratz K, Broaddus R and Li J: HE4
transcription- and splice variants-specific expression in
endometrial cancer and correlation with patient survival. Int J Mol
Sci. 14:22655–22677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Chen H, Mariani A, Chen D, Klatt E,
Podratz K, Drapkin R, Broaddus R, Dowdy S and Jiang SW: HE4 (WFDC2)
promotes tumor growth in endometrial cancer cell lines. Int J Mol
Sci. 14:6026–6043. 2013. View Article : Google Scholar : PubMed/NCBI
|
